Catalyst Event
Medpace Holdings Inc (MEDP) · Earnings Release
From KEDI Global Longevity Bio Index (KGLB)
4/20/2026, 12:00:00 AM
First quarter 2026 earnings release scheduled. Analysts forecast EPS around $3.90 to $4.01 estimated. Medium importance assigned as earnings typically drive significant volatility; event is scheduled.
Korean Translation
2026년 1분기 실적 발표 예정됨. 분석가들은 주당순이익(EPS)을 약 3.90달러에서 4.01달러로 예상함. 실적 발표는 통상적으로 높은 변동성을 수반하므로 중요도를 'Medium'으로 설정함. 이에 따라 실적 발표가 예정됨.
Related Recent Events
Biogen Inc (BIIB) · Other
U.S. FDA decision on LEQEMBI IQLIK (subcutaneous) for treatment initiation is scheduled. The FDA granted Priority Review for this supplemental Biologics License Application, with a PDUFA action date of May 24, 2026, which is expected. This event is expected to have a high price impact due to the significant market potential of the new delivery method.
5/24/2026, 12:00:00 AM
Novo Nordisk A/S (NVO) · Earnings Release
First quarter 2026 earnings release on May 6, 2026, scheduled.
5/6/2026, 12:00:00 AM
Leidos Holdings Inc (LDOS) · Earnings Release
Q1 2026 earnings release is scheduled. Impact is estimated to be low as it is a routine quarterly announcement.
5/5/2026, 12:00:00 AM
Merck and Co Inc (MRK) · Earnings Release
Merck & Co. is expected to release its Q1 2026 earnings results on or around April 30, 2026, before the market opens. High impact expected as earnings releases often drive price movements exceeding 10%, scheduled.
4/30/2026, 12:00:00 AM
Bristol-Myers Squibb Co (BMY) · Earnings Release
Q1 2026 earnings release is scheduled.
4/30/2026, 12:00:00 AM
Teva Pharmaceutical Industries Ltd (TEVA) · Earnings Release
Teva announced it will release its financial results for the first quarter of 2026 on April 29, 2026, scheduled. Low price impact expected for this routine announcement.
4/29/2026, 12:00:00 AM